Publication: Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review)
Issued Date
2011-09-01
Resource Type
ISSN
17921015
17920981
17920981
Other identifier(s)
2-s2.0-79960267924
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 771-775
Suggested Citation
Kiyoshi Kikuchi, Ko Ichi Kawahara, Hisaaki Uchikado, Naohisa Miyagi, Terukazu Kuramoto, Tomoya Miyagi, Yoko Morimoto, Takashi Ito, Salunya Tancharoen, Naoki Miura, Kazunori Takenouchi, Yoko Oyama, Binita Shrestha, Fumiyo Matsuda, Yoshihiro Yoshida, Shinihiro Arimura, Kentaro Mera, Ko Ichi Tada, Narimasa Yoshinaga, Ryuichi Maenosono, Yoshiko Ohno, Teruto Hashiguchi, Ikuro Maruyama, Minoru Shigemori Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review). Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 771-775. doi:10.3892/etm.2011.281 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/11482
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review)
Author(s)
Kiyoshi Kikuchi
Ko Ichi Kawahara
Hisaaki Uchikado
Naohisa Miyagi
Terukazu Kuramoto
Tomoya Miyagi
Yoko Morimoto
Takashi Ito
Salunya Tancharoen
Naoki Miura
Kazunori Takenouchi
Yoko Oyama
Binita Shrestha
Fumiyo Matsuda
Yoshihiro Yoshida
Shinihiro Arimura
Kentaro Mera
Ko Ichi Tada
Narimasa Yoshinaga
Ryuichi Maenosono
Yoshiko Ohno
Teruto Hashiguchi
Ikuro Maruyama
Minoru Shigemori
Ko Ichi Kawahara
Hisaaki Uchikado
Naohisa Miyagi
Terukazu Kuramoto
Tomoya Miyagi
Yoko Morimoto
Takashi Ito
Salunya Tancharoen
Naoki Miura
Kazunori Takenouchi
Yoko Oyama
Binita Shrestha
Fumiyo Matsuda
Yoshihiro Yoshida
Shinihiro Arimura
Kentaro Mera
Ko Ichi Tada
Narimasa Yoshinaga
Ryuichi Maenosono
Yoshiko Ohno
Teruto Hashiguchi
Ikuro Maruyama
Minoru Shigemori
Abstract
Edaravone was originally developed as a potent free radical scavenger and has been widely used to treat cerebral infarction in Japan since 2001. Several free radical scavengers have been developed and some of them have progressed to clinical trials for the treatment of cerebral infarction. One such scavenger, edaravone, has been approved by the regulatory authority in Japan for the treatment of patients with cerebral infarction. Of particular interest is the ability of edaravone to diffuse into the central nervous system in various neurologic diseases. Aside from its hydroxyl radical scavenging effect, edaravone has been found to have beneficial effects on inflammation, matrix metalloproteinases, nitric oxide production and apoptotic cell death. Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. The proven safety of edaravone following 9 years of use as a free radical scavenger suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.